| Name | AZ-PFKFB3-67 |
| Description | AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with an IC50=11nM for PFKFB3, reduces MCL-1, and inhibits angiogenesis by decreasing lactic acid production and ATP levels in endothelial cells (ECs) in tube-forming assays, and has neuroprotective effects. |
| In vitro | AZ-PFKFB3-67 is a highly selective PFKFB3 inhibitor with strong target inhibitory activity, exhibiting IC₅₀ values of 1.13 μM for PFKFB1, 0.159 μM for PFKFB2, and 0.011 μM for PFKFB3. In cellular assays, AZ-PFKFB3-67 inhibits fructose-2,6-bisphosphate (F-2,6-BP) production with an IC₅₀ of 0.281 μM, while having minimal effect on cellular lactate levels (IC₅₀ > 30 μM), indicating a pronounced inhibitory effect on early glycolytic regulation[1]. |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (4.39 mM), Sonication is recommended.
DMSO : 80 mg/mL (175.63 mM), Sonication is recommended.
|
| Keywords | AZ-PFKFB3-67 | AZ-PFKFB-3-67 | AZPFKFB367 | AZ PFKFB3 67 |
| Inhibitors Related | Cyanoacetamide | Pendimethalin | β-Glycerophosphate disodium salt pentahydrate | Hexane-1,6-diol | D-(-)-3-Phosphoglyceric acid disodium | Cyclosporine | Tartaric acid disodium dihydrate | Stearic acid | Venetoclax | L-Ascorbic acid 2-phosphate magnesium | Cyclosporin A | β-Glycerophosphate disodium salt hydrate |
| Related Compound Libraries | Bioactive Compound Library | Kinase Inhibitor Library | Multi-Target Compound Library | Post-Translational Modification Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |
United States
